Specializes in glaucoma, which is common in AsiansDevelops treatment for non-alcoholic steatohepatitis Secured multiple chemical anticancer toxin molecules(For more information, please refer to the link below)http://news.hankyung.com/article/read/201811224326f
‘pH Pharma’s Global Strategy’. The reason why licensing-in of German and Belgian new drug candidates
Hoyoung Huh, CEO, who has experience in IPO, M&A in global biotech, founded pH Pharma in 2015..licensing-in of new drug candidates from around the world, development within short-term and technology transfer strategy..phase 2b for glaucoma treatment completed and phase 1b for Non-alcoholic steatohepatitis treatment progressed(For more information, please refer to...
VC investment is “active” with government’s supports … KRW 630 billion reached in the first quarter
Investment balance expected to exceed 8 trillion this year, high interest in ICT service and bio.This year, the venture capital (VC) industry is showing active investment activities. It is interpreted that the increase in investments such as government funds and sufficient investment resources had an effect.(For more information, please refer...
Announcement of extraordinary shareholders’ meeting
To the shareholders of PH Pharma Co., Ltd. pH Pharma Co., Ltd. is holding an extraordinary general shareholders' meeting, so please attend. *Please check the attached file for details. download download
1Q Venture Fund to Bioand Medical Soaring and Hallyu Losing
In the first quarter of this year, venture funds were found to be concentrated in biomedical and medical treatment. On the other hand, investment in Hallyu content, which increased every year until last year, was reported to be decreasing.(For more information, please refer to the link below)http://news.mk.co.kr/newsRead.php?&year=2017&no=281527
The glare of hope for glaucoma… The development of new drugs in 20 years
(For more information, please refer to the link below)http://news.mk.co.kr/newsRead.php?&year=2017&no=281527
Prof. Kiho Park, Chairman of Department of Ophthalmology of Seoul National University Hospital, says “I am looking forward to new drugs for patients with normal tension glaucoma.”
(For more information, please refer to the link below)https://health.chosun.com/site/data/html_dir/2017/05/12/2017051201256.html
The landscape of VC investment is changing… Bio and medical investments ranked first
The biotechnology industry accounted for 22% of VC investment last year, ranking first over ICT… VCs eyes on bio ventures this year.(For more information, please refer to the link below)http://www.mt.co.kr/view/mtview.php?type=1&no=2017020211010373584&outlink=1